findmyKOL

Elinor Mody, MD

Basic profile

Reliant Medical Group

ORCIDNone on fileNPI
RegionWorcester, MA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2023Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Elinor Mody is a Rheumatology/Immunology physician affiliated with Reliant Medical Group. OpenAlex indexes 35 publications with 763 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
35publications

Distinct works indexed by OpenAlex.

763citations

Total citations across indexed works.

11h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

5 Neponset St
Worcester, MA 016062714

Telephone

508-595-2855

Registry record last updated 12 Mar 2019.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    53.7%
    RANK Ligand Inhibitor50%
    Denosumab100%
    Part B, office-administered33 patients
    Xanthine oxidase inhibitor2.2%
    Allopurinol88%Febuxostat13%
    Part D<11 patients

    + 2 more classes in this area

  • Cancer & immunology

    25.6%
    TNF inhibitor10.6%
    Enbrel Sureclick46%Humira(Cf) Pen36%Enbrel6%Humira(Cf)3%Enbrel Mini3%Humira2%Cimzia (2 Pack)2%Humira Pen2%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor8.4%
    Methotrexate100%
    Part D125 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    12%
    Corticosteroid9.7%
    Prednisone100%
    Part D144 patients
    Antidiarrheal microorganisms1.7%
    Folic Acid100%
    Part D26 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”